Status:
TERMINATED
Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors
Lead Sponsor:
Humanity & Health Medical Group Limited
Collaborating Sponsors:
Beijing 302 Hospital
Kindai University Faculty of Medicine
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to evaluate the efficacy of lenvatinib in HCC subjects who have progressive disease after first line treatment with checkpoint inhibitors. Approximately 20 subjects wil...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old on the day of consent
- Capable of understanding and complying with the protocol requirements and signed informed consent
- Documented histological or cytological diagnosis of HCC
- HCC progression after first line treatment with checkpoint inhibitors per RECIST 1.1
Exclusion
- Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma
- Prior TKI treatment
Key Trial Info
Start Date :
July 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04428437
Start Date
July 2 2022
End Date
September 30 2023
Last Update
October 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Humanity & Health Clinical Trial Centre
Hong Kong, Hong Kong SAR, Hong Kong